Amundi’s Ocular Therapeutix OCUL Stock Holding History

Amundi’s Portfolio OCUL Stock Details OCUL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$89.7K	Hold	10,589	–	–	﹤0.01%	1961
2025 Q4	$129K	Buy	+10,589	New	+$129K	﹤0.01%	1795

Other funds holding OCUL

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Summer Road West Palm Beach, Florida $142M AUM 43.61% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Amundi's OCUL Position: Q1 2026 in Review

Amundi held its Ocular Therapeutix (OCUL) position steady in Q1 2026 at 10,589 shares worth $89.7K. The position accounts for ﹤0.01% of the portfolio, ranked #1961.

Amundi first reported a position in OCUL in Q4 2025 and has held it in 2 quarters since. The position peaked at $129K in Q4 2025. 269 funds tracked by Wall St. Rank hold OCUL as of Q1 2026.

Amundi held 10,589 shares of Ocular Therapeutix worth $89.7K as of Q1 2026.
Amundi left its Ocular Therapeutix share count unchanged in Q1 2026.
Ocular Therapeutix made up ﹤0.01% of Amundi's portfolio in Q1 2026, its #1961 holding.
Amundi first reported a position in Ocular Therapeutix in Q4 2025 and has held it in 2 quarters since.
Amundi's Ocular Therapeutix position peaked at $129K in Q4 2025.
269 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q1 2026.

Based on Amundi's 13F filing for Q1 2026, filed 18 May 2026.